If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Phenibut, sold under the brand name Anvifen among others, is a central nervous system (CNS) depressant with anxiolytic effects, and is used to treat anxiety, insomnia, and for a variety of other indications. It is usually taken orally (swallowed by mouth), but may be given intravenously. Side effects of phenibut can include sedation, sleepiness, nausea, irritability, agitation, dizziness, euphoria, and sometimes headache, among others. Overdose of phenibut can produce marked central nervous system depression including unconsciousness. The medication is structurally related to the neurotransmitter γ-aminobutyric acid (GABA), and hence is a GABA analogue. Phenibut is thought to act as a GABAB receptor agonist, similarly to baclofen and γ-hydroxybutyrate (GHB). However, at low concentrations, phenibut mildly increases the concentration of dopamine in the brain, providing stimulatory effects in addition to the anxiolysis. Phenibut was developed in the Soviet Union and was introduced for medical use in the 1960s. Today, it is marketed for medical use in Russia, Ukraine, Belarus, Kazakhstan, and Latvia. The medication is not approved for clinical use in the United States and most of Europe, but it is sold on the Internet as a supplement and purported nootropic. Phenibut has been used recreationally and can produce euphoria as well as addiction, dependence, and withdrawal. It is a controlled substance in Australia, and it has been suggested that its legal status should be reconsidered in Europe as well.
== History == The efficacy of azacitidine to treat juvenile myelomonocytic leukemia was evaluated in AZA-JMML-001 (NCT02447666), an international, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine prior to hematopoietic stem cell transplantation in 18 pediatric patients with juvenile myelomonocytic leukemia.
===== Mice ===== Researchers at the Department of Pharmacology and Medical Chemistry used serotonergic drugs on male mice to study the effects of selected drugs on their behavior. Mice in isolation exhibit increased levels of agonistic behavior towards one another. Results found that serotonergic drugs reduce aggression in isolated mice while simultaneously increasing social interaction. Each of the treatments use a different mechanism for targeting aggression, but ultimately all have the same outcome. While the study shows that serotonergic drugs successfully target serotonin receptors, it does not show specifics of the mechanisms that affect behavior, as all types of drugs tended to reduce aggression in isolated male mice. Aggressive mice kept out of isolation may respond differently to changes in serotonin reuptake.
The 550-metre (1,804 ft) Crystal Palace pneumatic railway was exhibited at the Crystal Palace in 1864. This was a prototype for a proposed Waterloo and Whitehall Railway that would have run under the River Thames linking Waterloo and Charing Cross. Digging commenced in 1865 but was halted in 1868 due to financial problems. In 1867 at the American Institute Fair in New York, Alfred Ely Beach demonstrated a 100-foot (30 m) long, 6-foot (1.8 m) diameter pipe that was capable of moving 12 passengers plus a conductor. One year after New York City's first-ever elevated rail line went into service; in 1869, the Beach Pneumatic Transit Company of New York secretly constructed a 312-foot (95 m) long, 8.9-foot (2.7 m) diameter pneumatic subway line under Broadway, to demonstrate the possibilities of the new transport mode. The line only operated for a few months, closing after Beach was unsuccessful in getting permission to extend it – Boss Tweed, a corrupt influential politician, did not want it to go ahead as he was intending to personally invest into competing schemes for an elevated rail line.
Sources: en.wikipedia.org
Regulatory guidance from the FDA recommends that sponsors of oligonucleotide drug applications assess DDI potential through in vitro transporter studies and, where indirect CYP modulation is plausible, through induction assays, even when direct CYP inhibition is absent.
The hypothesis was put forward in 2012 and Benton, et al. named the cycle in 2017 after its inventor, the Swiss biochemist, nutritionist and exercise physiologist Dr. Serge Summermatter. The concept of the Summermatter cycle finds broad application in body weight management to time exercise interventions and avoid catch-up fat (yo-yo effect). The recent advances in the treatment of obesity (e.g., GLP-1 and GIP agonists like Ozempic, Wegovy etc.) has further spurred interest in the Summermatter cycle. Treatments with incretins like semaglutide induce not only fat but also muscle mass loss. The suppressed thermogenesis described by the Summermatter cycle explains the weight and fat regain in patients that discontinue incretins. Moreover, the concept is used by elite athletes to optimally coordinate their training bouts and energy intake.
organometallic chemistry, compounds with metal-carbon bonds. This area touches on organic synthesis, which employs many organometallic catalysts and reagents. cluster chemistry, compounds with several metals bound together with metal–metal bonds or bridging ligands. bioinorganic chemistry, biomolecules that contain metals. This area touches on medicinal chemistry. materials chemistry and solid state chemistry, extended (i.e. polymeric) solids exhibiting properties not seen for simple molecules. Many practical themes are associated with these areas, including ceramics.
Ronnie O'Sullivan wins the 2024 Masters after beating Ali Carter, making him both the youngest and oldest winner in the tournament's history. He won his first title in the 1995 Masters when he was 19 years old. 29 years later, he wins his eighth at the age of 48. 15 January The portrait of King Charles III for use on public buildings, such as courts and government offices is unveiled. Another week of strike action is announced by the ASLEF train drivers union, to run from Tuesday 30 January until Monday 5 February. The Home Office announces that it will proscribe the radical Islamist group Hizb ut-Tahrir as a terrorist organisation, accused of praising the Hamas attacks. A review into investigations conducted by Greater Manchester Police between 2004 and 2019 finds that girls were "left at the mercy" of paedophile grooming gangs for several years because of failings by senior police and council bosses. Alison Phillips confirms she will stand down as editor of the Daily Mirror at the end of January, having been in the role since 2018. 16 January Schools are closed and commuters face disruption following snowfall across parts of the UK. Lee Anderson and Brendan Clarke-Smith resign their positions as Deputy Chairmen of the Conservative Party, after saying they would back rebel amendments on the Rwanda bill. Jane Stevenson also resigns as a Parliamentary Private Secretary so she can vote for the amendment.
== Synthesis == The protein component of proteoglycans is synthesized by ribosomes and translocated into the lumen of the rough endoplasmic reticulum. Glycosylation of the proteoglycan occurs in the Golgi apparatus in multiple enzymatic steps. First, a special link tetrasaccharide is attached to a serine side chain on the core protein to serve as a primer for polysaccharide growth. Then sugars are added one at a time by glycosyl transferase. The completed proteoglycan is then exported in secretory vesicles to the extracellular matrix of the tissue.
Sources: en.wikipedia.org
== Views on religion == Crick referred to himself as a humanist, which he defined as the belief "that human problems can and must be faced in terms of human moral and intellectual resources without invoking supernatural authority." He publicly called for humanism to replace religion as a guiding force for humanity, writing:
=== Non-medical use === Vosilasarm and other SARMs are sold on the black market on the Internet. Aside from vosilasarm, the other most commonly used SARMs include enobosarm (ostarine; GTx-024, S-22), LGD-4033 (VK5211; "ligandrol"), and andarine (GTx-007; S-4). Social media has played an important role in facilitating the widespread non-medical use of SARMs.
The European Aviation Safety Agency (EASA) is tasked by Article 15(4) of Regulation (EC) No 216/2008 of the European Parliament and of the Council of February 20, 2008, to provide an annual review of aviation safety. The Annual Safety Review presents statistics on European and worldwide civil aviation safety. Statistics are grouped according to type of operation, for instance, commercial air transport, and aircraft category, such as aeroplanes, helicopters, gliders, etc. The Agency has access to accident and statistical information collected by the International Civil Aviation Organization (ICAO). States are required, according to ICAO Annex 13, on Aircraft Accident and Incident Investigation, to report to ICAO information, on accidents and serious incidents to aircraft with a maximum certificated take-off mass (MTOM) over 2250 kg. Therefore, most statistics in this review concern aircraft above this mass. In addition to the ICAO data, a request was made to the EASA Member States to obtain light aircraft accident data. Furthermore, data on the operation of aircraft for commercial air transport were obtained from both ICAO and the NLR Air Transport Safety Institute.
In jaundice owing to hemolysis (prehepatic, or hemolytic, jaundice), the pathophysiology is that overproduction of bilirubin from the extravascular or intravascular hemolysis overwhelms the capacity of the liver to excrete it. The bilirubin present in the plasma is largely unconjugated in this setting as they haven't been taken up and conjugated by the liver. In this case, total serum bilirubin increases while the ratio of direct bilirubin to indirect bilirubin remains 96 to 4 as up to 96%-99% of bilirubin in the bile are conjugated mentioned above. Although there were some studies that showed an inverse correlation between serum bilirubin level and prevalences of ischemic coronary artery disease, cancer mortality, or colorectal cancer in general population, the potential benefits of the chemopreventive function of bilirubin and their causative relations haven't been proved.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.